Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis

Published:2023-09 Issue: Volume:186 Page:109805
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Salvestrini Viola,Kim Kyubo,Caini Saverio,Alkner Sara,Ekholm Maria,Skyttä Tanja,Becherini Carlotta,Coles Charlotte E.,Kaidar-Person Orit,Offersen Birgitte,de Azambuja Evandro,Visani Luca,Cortes Javier,Harbeck Nadia,Rugo Hope S.,Isacke Clare M.,Marangoni Elisabetta,Morandi Andrea,Lambertini Matteo,Poortmans Philip,Livi Lorenzo,Meattini Icro

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference46 articles.

1. HER2-positive breast cancer;Loibl;Lancet,2017

2. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

3. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010

4. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells;Asanuma;Cancer Res,2005

5. Antibody-drug conjugates in breast cancer: the chemotherapy of the future?;Nicolo;Curr Opin Oncol,2020

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of radionecrosis in HER2-positive breast cancer with brain metastasis receiving trastuzumab emtansine (T-DM1) and brain stereotactic radiosurgery;Radiotherapy and Oncology;2024-10

2. Long-Term Success With a TDM-1 Biosimilar in Recurrent HER2-Positive Breast Cancer With Multisite Metastases: A Comprehensive Case Study;Cureus;2024-08-16

3. Dermatologic toxicities of antibody-drug conjugates;Journal of the American Academy of Dermatology;2024-08

4. Concurrent antibody–drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials;ESMO Open;2024-07

5. Efficacy and safety of antibody–drug conjugates in the treatment of urothelial cell carcinoma: a systematic review and meta-analysis of prospective clinical trials;Frontiers in Pharmacology;2024-06-12